Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chiome Bioscience Inc.
  6. News
  7. Summary
    4583   JP3205350006


SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Chiome Bioscience : Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development

05/14/2021 | 11:09am EDT

May 14, 2021

Company: Chiome Bioscience Inc.

Representative: Shigeru Kobayashi, President & CEO

(Code: 4583, Tokyo Stock Exchange Mothers)

Inquiries: Arihiko Bijohira, Executive Director & CFO

Phone: +81-3-6383-3746

Collaborative Research Agreement with Mologic Ltd. for antibody discovery and development

Chiome Bioscience Inc. ("Chiome") announced today that Chiome and Mologic Ltd. ("Mologic", headquartered in Bedfordshire, United Kingdom) have entered into a Collaborative Research Agreement for antibody discovery and development for use in advanced diagnostic tests.

Under this Collaborative Research Agreement for up to 1 year, Chiome will generate specialised antibodies against several novel diagnostic biomarker targets by means of the ADLib® system, Chiome's proprietary antibody generation technology. "This technology is uniquely well suited to in vitro discovery of antibodies that recognize important but obscure or subtle antigenic features, which can make a positive difference to the performance of diagnostic tests.", commented Professor Paul Davis, Co-Founder and Chief Scientific Officer of Mologic. Mologic will characterize and evaluate the antibodies for application in its advanced diagnostic test platforms. Based on this comprehensive collaboration agreement, Chiome expects to directly contribute to Mologic's leading edge diagnostic work for maximum positive impact on global public health. There is a strong and growing demand for accurate and rapid diagnostic products throughout the world, especially in low to middle income countries (LMICs) suffering from a burden of debilitating infectious diseases, such as tuberculosis and malaria.

Chiome will receive research fees from Mologic, and royalties from the profit-making diagnostic products, based on the specialized properties of Chiome antibodies sold in the developed world. Full financial details are not being disclosed.

About Mologic>(https://mologic.co.uk/

Mologic is a leading developer of advanced lateral flow and rapid diagnostic technologies. Leveraging its core technology platforms, the Company works with global organisations, researchers and clinicians to help them deliver fast, reliable and accurate diagnosis at the point-of-need.

Mologic offers world-leading technology and scientific research expertise for contract research and development, alongside a portfolio of device and reagent products for clinical applications. The Company also helps organisations to scale-up manufacturing from initial prototyping through low to mid-scale production. Mologic's science has broad application across markets and disease states where rapid, accurate point-of-need testing can help make a difference in patient care and patient outcomes.

Mologic is conducting innovative exploratory science for step change technology through its Centre for Advanced Rapid Diagnostics (CARD). The aim is to develop (and make accessible) the next- generation of ultra-sensitivepoint-of-need diagnostics which are easy to use and low cost to manufacture - critical to the success of many global health programmes.

About ADLib® system technology

The ADLibsystem offers a platform library with unique array space that adds seamless Affinity maturation function. It is a rapid one stop order drug discovery and research tool that can complete

- 1 -

all the steps necessary for antibody drug discovery such as selection, full-length IgG expression, humanization, and affinity maturation on one in-vitro platform.

- 2 -


Chiome Bioscience Inc. published this content on 14 May 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 May 2021 15:08:12 UTC.

ę Publicnow 2021
08/13CHIOME BIOSCIENCE : Supplement Documents for Financial Results Q2 FY12/21
08/13CHIOME BIOSCIENCE : Non-Consolidated Financial Results (Japanese GAAP) for the Six Months ..
08/13Chiome Bioscience Inc. Reports Earnings Results for the Half Year Ended June 30, 2021
05/14CHIOME BIOSCIENCE : Termination of Collaborative Development License and Exclusive Option ..
05/14CHIOME BIOSCIENCE : Non-Consolidated Financial Results (Japanese GAAP) for the Three Month..
05/14CHIOME BIOSCIENCE : Supplement Documents for Financial Results Q1 FY12/21
05/14CHIOME BIOSCIENCE : Collaborative Research Agreement with Mologic Ltd. for antibody discov..
05/14Chiome Bioscience Inc. Announces Collaborative Research Agreement with Mologic Ltd. for..
05/14Chiome Bioscience Inc. Announces Non-Consolidated Earnings Results for the Three Months..
05/14Chiome Bioscience Inc. Announces Termination of Collaborative Development License and E..
More news
Sales 2020 600 M 5,42 M 5,42 M
Net income 2020 -1 400 M -12,6 M -12,6 M
Net Debt 2020 - - -
P/E ratio 2020 -6,19x
Yield 2020 -
Capitalization 9 632 M 87,0 M 87,0 M
Capi. / Sales 2020 16,1x
Capi. / Sales 2021 13,2x
Nbr of Employees 53
Free-Float 94,2%
Duration : Period :
Chiome Bioscience Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHIOME BIOSCIENCE INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus -
Number of Analysts 0
Last Close Price 239,00 
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Shigeru Kobayashi President & Representative Director
Akiyuki Furuya Independent Outside Director
Haruhisa Kubota Independent Outside Director
Arihiko Bijohira Director & Manager-Corporate Planning Office
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.311.74%173 624
LONZA GROUP AG30.56%59 611
CELLTRION, INC.-23.54%31 745
SEAGEN INC.-7.88%29 353